AFT Pharmaceuticals has been notified of a decision by the European Medicines Agency to approve its Maxigesic paracetamol-ibuprofen combination analgesic for sale in Austria, Belgium, France, Croatia, Germany, Luxembourg, the Netherlands, Portugal and Spain.
AFT ceo Hartley Atkinson said receiving regulatory approval in the nine additional countries would open up significant opportunities.
France is the second largest potential market in the world after the USA, while the nine additions collectively currently account for over US$1.8 billion in annual sales of paracetamol and ibuprofen.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 May 17